PRME today
$3.81-$0.49 (-11.33%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourLeaning Bullish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $21.67
Key levels
Resistance$18.26
Resistance$17.66
Latest news & SEC filings
DealPrime Medicine Sets Terms for Common Stock Sale to the Public
DealPrime Medicine Proposes $125 Million Public Stock Offering
DealPrime Medicine starts $125M common stock offering
All PRME news →About Prime Medicine
Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing technology that makes targeted changes to DNA without double-stranded breaks. Its pipeline includes in vivo programs for liver diseases such as Wilson disease and alpha-1 antitrypsin deficiency, cystic fibrosis programs, and an ex vivo program for chronic granulomatous disease. The company also collaborates with Bristol-Myers Squibb on ex vivo T-cell engineering and with the Cystic Fibrosis Foundation. It operates in the United States.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Prime Medicine, Inc. (PRME)
What Is the Price Target for PRME?
SEPT Low Target
$7.65
SEPT Mid Target
$9.00
SEPT High Target
$10.35
Analyst Consensus
$9.00
Is PRME a Buy or Sell Right Now?
Thesis
- •Revenue growing 55.3% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PRME.
Start Free Trial →Is PRME Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$6.88
7
Moat Score
NONE
3/9
Piotroski Score
-3.0
Altman Z-Score
What Is Smart Money Doing with PRME?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PRME Growth Story
Revenue YoY
55.3%
3yr Revenue CAGR
N/A%
EPS Growth YoY
18.18%
FCF Growth YoY
-28.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for PRME
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PRME, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:42:51 | $3.83 | 5,000 | $$19K | MIDPOINT |
| 14:42:37 | $3.83 | 1,002 | $$4K | BUY |
| 14:42:34 | $3.86 | 1,000 | $$4K | BUY |
| 14:42:30 | $3.85 | 1,500 | $$6K | SELL |
| 14:42:10 | $3.87 | 1,000 | $$4K | MIDPOINT |
5 dark pool trades shown · $$36K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Prime Medicine, Inc. (PRME) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PRME — frequently asked questions
What is PRME stock price today?
Prime Medicine, Inc. (PRME) is at $3.81, down 11.33% (-$0.49) at the Nov 12, 2026 close.
Why is PRME stock moving today?
Latest PRME news — Nov 11, 2026: Prime Medicine Sets Terms for Common Stock Sale to the Public · Nov 10, 2026: Prime Medicine Proposes $125 Million Public Stock Offering
What is the PRME price target?
The average analyst price target for PRME is $9.00, ranging from $8 to $9, based on 3 analysts. Latest: BMO Capital initiates on Aug 19, 2026.
What do analysts rate PRME?
Analyst ratings for PRME: 1 Buy, 2 Hold, 0 Sell — consensus Hold.
Did PRME beat earnings?
PRME last reported on Aug 6, 2026: EPS -$0.24 vs -$0.26 expected — a beat of 6.7%.
Does PRME pay a dividend?
PRME does not currently pay a dividend.
What are PRME support and resistance levels?
Resistance: $17.66, $18.26, $19.28.
What are insiders doing with PRME?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PRME?
Nov 11, 2026: Prime Medicine Sets Terms for Common Stock Sale to the Public · Nov 10, 2026: Prime Medicine Proposes $125 Million Public Stock Offering · Nov 10, 2026: Prime Medicine starts $125M common stock offering